In Massachusetts, Audax Medical, Inc. has a worldwide license from Northeastern University for new nanotechnology of a self-assembling arginine-rich peptide to add to its current tissue regeneration platform. They plan to use this new nanotech for their medical applications and tissue regeneration. The newly developed nanostructures have antimicrobial properties, but unlike antibiotics which go after specific cellular activity, the nanoparticles aim specifically for the microorganisms’ cytoplasmic membrane which limits the inflammation and infection in surrounding tissue. Mark Johanson, Audax’s CEO, told PR Newswire, “We are excited to be collaborating with Northeastern’s team of world-class researchers. This technology fits perfectly with our company’s core biologics platform, while expanding potential clinical opportunities in the growing Wound Care and Anti-Infection markets.”
Latest article
You better be-leaf it: Dawn Bio cultivates wood in a petri dish
In the Netherlands, a startup based at Wageningen University’s campus is pioneering technology to produce wood from cultured cells.
Dubbed Dawn Bio, the company has...
Algae-based snowboards from WNDR get nod from Time Magazine
In Utah, WNDR Alpine’s algae-based snowboards have been named to Time Magazine’s top 200 inventions list.
Unlike most snowboards, which are made out of petroleum-based...
Prince William’s Earthshot Prize names seaweed firm Coast 4C as a finalist
In Australia, a startup sustainably cultivating seaweed has been chosen as a finalist for Prince William’s 2024 Earthshot Prize.
Coast 4C works with farmers in...